Acceleron (XLRN) option implied volatility flat into Phase III Believe results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
July 12, 2018 7:10 AM EDTAcceleron Pharma Inc. (NASDAQ: XLRN) today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Companys locally acting Myostatin+ muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).
We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need, said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron. We believe that ACE-083 could become an important new treatment for patients with FSHD whose muscle weakness negatively affects their... More
Acceleron Pharma (XLRN) PT Raised to $62 at UBS
July 10, 2018 8:01 AM EDTUBS raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $62.00 (from $57.00) while maintaining a Buy rating.
... MoreAcceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results
July 10, 2018 7:34 AM EDTH.C. Wainwright raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $74.00 (from $69.00) while maintaining a Buy rating following the company's announcement, along with Celgene (NASDAQ: CELG), of positive results from the Phase 3 BELIEVE study of luspatercept in... More
